<?xml version="1.0" encoding="UTF-8"?>
<snippetsTree>
 <snippets file="drugDebug/PMC6907871/results/search/test_trace/results.xml">
  <result pre="antiviral agents against Kaposi’s sarcoma-associated herpesvirus (KSHV) by high-throughput drug" exact="screening" post="reveals the role of histamine-related signaling in promoting viral"/>
  <result pre="as Kaposi’s sarcoma (KS) and primary effusion lymphoma (PEL). Current" exact="treatment" post="options for KSHV infection and virus associated diseases are"/>
  <result pre="and primary effusion lymphoma (PEL). Current treatment options for KSHV" exact="infection" post="and virus associated diseases are sometimes ineffective, therefore, more"/>
  <result pre="and oncogenesis. In this study, we have established a high-throughput" exact="screening" post="assay by using an inducible KSHV+ cell-line, iSLK.219. After"/>
  <result pre="screening assay by using an inducible KSHV+ cell-line, iSLK.219. After" exact="screening" post="a compound library that consisted of 1280 Food and"/>
  <result pre="herpesvirus. Author summary As a major oncogenic human herpesviruses, KSHV" exact="infection" post="causes several cancers mostly seen in immunocompromised patients. Currently,"/>
  <result pre="tricks&quot; approach may serve as a feasible strategy for high-throughput" exact="screening" post="of novel agents against lytic replication of KSHV. Here"/>
  <result pre="human herpesviruses, KSHV has two alternating life-cycle programs following primary" exact="infection" post="in host cells, the latent and lytic phases, which"/>
  <result pre="therapy, specifically targeting the KSHV lytic replication cycle in the" exact="treatment" post="and prevention of KSHV-associated diseases [20]. For example, treatment"/>
  <result pre="the treatment and prevention of KSHV-associated diseases [20]. For example," exact="treatment" post="with Ganciclovir (GCV) and Foscarnet (PFA) to block the"/>
  <result pre="replication is important in the development of virus-associated diseases, makes" exact="screening" post="and identifying new antiviral agents targeting viral lytic replication"/>
  <result pre="sought to screen for novel anti-KSHV agents using a high-throughput" exact="screening" post="strategy applied to a library consisting of 1280 Food"/>
  <result pre="consisting of 1280 Food and Drug Administration (FDA)-approved drugs. Our" exact="screening" post="finally identified 15 hit compounds with significant anti-KSHV activity."/>
  <result pre="although the roles of histamine-related signaling in regulation of KSHV" exact="infection" post="and replication are still unclear. Results Optimization and validation"/>
  <result pre="and validation of an in vitro system for anti-KSHV drug" exact="screening" post="To identify new antiviral agents against KSHV lytic replication,"/>
  <result pre="replication, the human iSLK.219 cell line was used as a" exact="screening" post="model. iSLK.219 carries a recombinant rKSHV.219 virus encoding a"/>
  <result pre="reports demonstrated that iSLK.219 cells are suitable for anti-KSHV drug" exact="screening" post="[31,32]. To optimize conditions for the induction of lytic"/>
  <result pre="as the optimal lytic-induction condition for subsequent antiviral screening. This" exact="treatment" post="also promoted the production of mature virions as detected"/>
  <result pre="detected using the HCS system at 48 h post-infection. High-throughput" exact="screening" post="identifies new antiviral agents against KSHV lytic replication and"/>
  <result pre="next sought to identify new antiviral agents using a high-throughput" exact="screening" post="strategy from a library that consisted of 1280 FDA-approved"/>
  <result pre="analyzed by the Operetta HCS System (Fig 2A). After primary" exact="screening" post="(Fig 2B), 132 of these compounds were identified as"/>
  <result pre="were also listed in Table 1. Fig 2 High-throughput drug" exact="screening" post="of new agents effectively blocking infectious virion production. (A)"/>
  <result pre="CC50 and SI (CC50/IC50) as described in Methods. (B) Primary" exact="screening" post="results of 1280 FDA-approved drugs against KSHV, which were"/>
  <result pre="Dox-induced RFP expression in a dose-dependent manner, although histamine alone" exact="treatment" post="showed no viral induction (Fig 5A). We also measured"/>
  <result pre="promotion of KSHV lytic replication. Our results confirmed that histamine" exact="treatment" post="enhanced the expression of representative viral lytic proteins, RTA,"/>
  <result pre="LANA and LANA2 (Fig 7). Next, we found that histamine" exact="treatment" post="led to increased activation-related phosphorylation of MAPK pathways (including"/>
  <result pre="a cohort of HIV-infected patients were measured using ELISA. KSHV" exact="infection" post="status in these patients was determined as described in"/>
  <result pre="saliva from cohort HIV-infected patients were quantified using ELISA. KSHV" exact="infection" post="status was identified as described in Methods. *** ="/>
  <result pre="pathogenesis. Discussion In the current study, we employed a high-throughput" exact="screening" post="assay to identify 15 FDA-approved drugs as new and"/>
  <result pre="new clues for the development of therapeutic strategies against KSHV" exact="infection" post="and related diseases. Among the hit compounds, Monobenzone, a"/>
  <result pre="is used to eliminate melanin from skin cells for clinical" exact="treatment" post="of people with vitiligo [34], is highly effective in"/>
  <result pre="potential to become an effective and safe drug for the" exact="treatment" post="of KSHV infection, although to our knowledge it has"/>
  <result pre="and rectal cancers, and Oxibendazole, a polymerase inhibitor for the" exact="treatment" post="of intestinal helminth infections, are largely dependent on their"/>
  <result pre="compared to healthy comparators. In conclusion, the lacking of effective" exact="treatment" post="for KSHV-associated malignancies, especially in immunocompromised patients, requires the"/>
  <result pre="obtained from Selleck Chemicals (Houston, TX, USA). High-throughput antiviral drug" exact="screening" post="A compound library consisted of 1280 FDA-approved drugs were"/>
  <result pre="deliver 10 μM (final concentration) of each drug to 384-well" exact="screening" post="plates using an acoustic dispensing Echo 550 instrument (Labcyte,"/>
  <result pre="cells treated by inducers or not were added to these" exact="screening" post="plates. The viral supernatants were collected at 48 h"/>
  <result pre="assays were performed using a Bio-Rad CFX384 Touch Real-Time PCR" exact="detection" post="system using the iTaq Universal SYBR Green Supermix (Bio-Rad)"/>
  <result pre="current study, a total of 37 HIV+ patients with antiretroviral" exact="treatment" post="(ART) in our HIV Outpatient (HOP) Clinic are involved."/>
  <result pre="heparin-coated tubes, and plasma was isolated by centrifugation. The KSHV" exact="infection" post="status was determined by using quantitative ELISA for identifying"/>
  <result pre="egress. J Virol76: 1537–1547. 10.1128/JVI.76.4.1537-1547.200211799148 34RordamOM, LenouvelEW, MaaloM (2012) Successful" exact="treatment" post="of extensive vitiligo with monobenzone. J Clin Aesthet Dermatol5:"/>
  <result pre="46PanH, XieJ, YeF, GaoSJ (2006) Modulation of Kaposi's sarcoma-associated herpesvirus" exact="infection" post="and replication by MEK/ERK, JNK, and p38 multiple mitogen-activated"/>
 </snippets>
</snippetsTree>
